

## INDEX

Note: Page numbers in *italics* indicate figures.  
Page numbers followed by a “t” indicate tables.  
Acronyms are used for the names of clinical trials and studies.

- 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. See *Statins*.  
12-HETE (hydroxyeicosatetraenoic) acid, 97
- AA. See *Arachidonic acid (AA)*.
- Abciximab (ReoPro), 161-165, 188. See also *Glycoprotein IIb/IIIa receptor antagonists*.  
in ACSs, 254t  
in AMI, 284, 285  
clinical experience, 162-165, 164t, 166, 175, 176t  
in combination with fibrinolytics, 75, 76, 284  
distinguishing characteristics, 172-174, 173t, 174, 175  
half-life, 161  
pharmacodynamics, 161, 163  
pharmacokinetics, 161  
TARGET trial, 136-137, 175, 176t  
thrombocytopenia and, 177, 392t
- ACC/AHA (American College of Cardiology/American Heart Association) guidelines, 76, 267t, 268t, 295-298, 297t, 312t-313t, 318t
- ACCP (American College of Chest Physicians) Consensus Conference recommendations, 76, 232, 268t, 319t, 360-361, 378
- ACE inhibitors, 253t, 316t
- Acenocoumarol, 54
- Acetaminophen, warfarin and, 55, 394, 395t
- Acquired platelet abnormalities, 184, 188, 188t
- Acquired thrombophilia, 219-224
- ACSs. See *Acute coronary syndromes (ACSs)*.
- Activated partial thromboplastin time. See *APTT*.
- Activated protein C (APC), 17, 18. See also *Protein C*.  
hirudins and, 47-52  
thrombophilia and, 221
- Activation/initiation events, 15-16, 17  
platelet activation, 25-27, 28
- Activators, plasminogen. See *Plasminogen activators*.
- ACTIVE-A trial, 354-355
- ACTIVE-W trial, 354-355
- ACUTY trial, 258
- Acute arterial insufficiency, 317-322
- Acute arterial occlusion, 322t
- Acute coronary syndromes (ACSs), 239-273  
clinical trials and research studies  
ACUTY, 258  
ASPECT-2, 296t, 297t  
CREDO, 140-144  
CURE, 140, 141, 142-143, 249  
ESSENCE, 251  
NICE, 289  
OASIS-5, 251-252  
REPLACE 2, 258  
TRITON-TIMI38, 249

Acute coronary syndromes (ACSs) (*continued*)

- clopidogrel and, 131, 140-145
- diagnosis, 241, 246-247
- epidemiology, 239
- hospitalizations for, yearly, 239
- hospitalized patients, 243-248
- management of, 248-259
  - algorithm for, 260-262, 300-301
  - anticoagulants, 249-252, 255t, 268t
  - antiplatelet therapy, 161-181, 249, 254t, 256t-257t
  - antithrombotic therapy, 248-259, 254t-255t
  - cardiac biomarkers and, 258
  - direct thrombin inhibitors, 252-258
  - early aggressive approach, 259, 263t-269t
  - fibrinolytic therapy, contraindication for, 258
  - LMWH, 289-291
  - medical management, 248, 253t, 261
  - oral anticoagulant therapy, 258
  - response variability and, 196
  - strategies for, 258-259, 260-262
  - summary of, 253t, 254t-255t, 300-301
- MI. See *Myocardial infarction (MI)*.
- NSTE, 239
- NSTEMI, 239-241, 240
- pathobiology, 239-241, 240
- patient characteristics, 241, 264t-266t, 267t
- plaque in, 239-241, 240
- prasugrel and, 152-153
- risk/probability of coronary artery disease, 241-243
  - electrocardiogram (ECG), 241, 242t, 243t, 244-247
  - risk factors, 241
  - risk stratification, 241-243, 248t, 250t-251t, 252, 258, 260
- TIMI risk scores, 242, 248t, 252
- TRITON, 145, 152-153, 154t-155t, 156, 158-159

Acute myocardial infarction (AMI), 275-306. See also *Myocardial infarction (MI)*.

- clinical trials and research studies
  - APRICOT-2, 296t, 297t
  - ASSENT-II, 278
  - CAPRIE, 276-277
  - CARS, 295, 296t, 297t
  - CHAMP, 296t, 297t
  - CLARITY, 277, 287, 288
  - COBALT, 281t
  - COMMIT/CCS-2, 277, 287
  - comparative trials, 278, 282, 290t-291t
  - CURE, 277
  - ExTRACT-TIMI, 289-291, 290
  - Fibrinolytic Therapy Trialists, 279
  - GISSI-2, 278
  - GUSTO, 278, 280t, 282, 285, 286
  - HORIZONS, 295
  - INJECT, 280t
  - International Study Group, 280t
  - INTRO-AMI, 284
  - ISIS-2 and -3, 275, 280t
  - NICE, 289

Acute myocardial infarction (AMI), clinical trials and research studies (*continued*)

- OASIS-6, 291
- PLATO, 295
- SPEED, 285
- WARIS, 295, 296t, 297t
- diagnostic measures, 283t
- management of, 283t
  - AHA/ACC guidelines for, 295-298, 297t
  - antiplatelet therapy, 275-277, 276
  - direct antithrombins, 289-291, 299t
  - fibrinolytic therapy, 277-278, 279-282, 282, 283t, 290t-291t
    - benefits of, 275
    - complications of, 279
    - mortality outcomes in, 280t-281t
  - goals, initial, 275
  - goals, long-term, 275
  - heparins, 282-291, 289t, 292-293
  - warfarin, 295-298, 296t, 297t
- primary PCI, 291-295
- reinfarction. See *Myocardial infarction (MI)*.
- STEMI, 240. See also *STEMI*.
- thrombolytic resistance and, 283-287, 284
- ADEPT-DES Registry, 201
- Adhesion tests, platelet, 184
- Adjunctive therapy, 76-79
- ADMIRAL trial, 165, 166
- ADP (adenosine diphosphate), 27, 83, 97
- ADP-mediated platelet inhibition, 151, 200, 202t-203t
- Adverse reactions, 392t. See also *Bleeding; Complications of antithrombotic therapy; and specific agents and classes of agents*.
- AF. See *Atrial fibrillation (AF)*.
- AFASAK trial, 354
- AFFIRM study, 347-348
- Age factors, 355, 356, 375, 393-394. See also *Elderly patients*.
- Aggrastat. See *Tirofiban (Aggrastat)*.
- Aggregometry, 105, 184
- AHA guidelines. See *ACC/AHA guidelines*.
- ALBION trial, 140
- Alcohol intake, 56t, 394
- Aldosterone, 404
- Allergic reactions
  - to aspirin, 91, 265, 318, 319t
  - to fibrinolytic agents, 279
  - to hirudins, 406
  - to streptokinase, 68t, 70, 279
  - to ticlopidine/clopidogrel, 116, 136
- Alopecia, 392t, 398, 404
- $\alpha$ -Granules, 27
- Alteplase, 65-66, 382-383, 383t
- American College of Cardiology. See *ACC/AHA guidelines*.
- American College of Chest Physicians. See *ACCP*.
- American Heart Association. See *ACC/AHA guidelines*.
- AMI. See *Acute myocardial infarction (AMI)*.
- Amiodarone, 56t, 395t
- Amplification/priming stage, 27, 28
- Androgens, 395t

- Anesthetics, 400t
- Angina, stable, 239, 240  
ticlopidine for, 117
- Angina, unstable, 239-241, 240. See also *Acute coronary syndromes (ACSs)*.  
antithrombotic agents for, 37t, 52  
aspirin for, 85  
high-risk features in, 248t  
secondary (NSTEMI), 239-241, 240  
ticlopidine for, 117  
TIMI risk score, 248t, 252
- Angiomax. See *Bivalirudin (Angiomax)*.
- Angioplasty, 77-79, 162, 291, 298  
peripheral, 96, 97, 106t, 321t
- Angiotensin converting enzyme inhibitors. See *ACE inhibitors*.
- Anisoylated plasminogen-streptokinase activator complex. See *Anistreplase (APSAC)*.
- Anistreplase (APSAC), 68t, 70-71, 71  
complications of, 407
- Annexins, 222
- Antacids, 56t
- Antibiotics, 56t, 394, 395t
- Anticardiolipin antibody, 374
- Anticoagulants. See also *Antithrombotic agents*.  
in ACSs, 249-252, 255t, 268t  
dosing for, 269t  
in AF, 346-351  
risks vs benefits, 353  
duration of treatment, 378-379  
in HIT, 402t  
monitoring. See *Monitoring*.  
outpatient therapy with, 360, 360t, 361  
in surgery, guidelines for, 400t  
therapeutic window and, 357, 358  
in TIAs and stroke, 309, 312t-315t  
transitioning between agents, 359  
under development, 57  
in valvular heart disease/thrombosis, 332-335
- Anticoagulation clinics, 357, 360t, 393
- Anti-inflammatories, 394, 395t
- Anti-ischemic therapy, 243-248
- Antiphospholipid antibody syndrome, 214t, 220t, 221-222, 224, 232
- $\alpha_2$ -Antiplasmin, 18, 19, 65, 66, 69
- Antiplatelet agents. See also *specific agents*.  
in ACSs, 249, 254t, 256t-257t  
actions of, 188  
administration of  
prior to alteplase (tPA), 66  
prior to PCI, 91  
in AF, 354-355  
in AMI, 275-277, 276  
aspirin, 83-113  
clopidogrel, 131-150  
in combination. See also *specific agents*.  
dual antiplatelet therapy, 196, 201  
complications of, 392t  
GP IIb/IIIa receptor antagonists, 161-181
- Antiplatelet agents (*continued*)  
intravenous, 254t  
monitoring effectiveness of, 183-194. See also *Platelet function testing*.  
oral, 254t  
in PAD, 320t-321t, 324  
periprocedural management of therapy, 206, 206t  
prasugrel, 151-160  
safety vs efficacy, balance of, 256t-257t  
in stroke and TIAs, 308-309, 310t-315t, 318t-319t  
ticlopidine, 115-130
- Antiplatelet Trialists Collaboration, 86-87, 307, 319
- Antipyretics, 395t
- Antithrombin (AT), 16t, 374  
deficiency. See *Thrombophilia*.  
gene mutations, 214t, 215, 217  
heparin potentiation of, 3
- Antithrombotic agents, 33-63, 188. See also *specific agents and classes of agents*.  
in ACSs, 249-252, 255t, 268t, 269t  
adjunctive to fibrinolytic therapy, 76-77  
clinical trials and research studies  
EPHESUS, 40  
EXPERT, 39, 40  
MATISSE, 39-41  
OASIS -5 and -6, 41-47, 42, 43, 44-45, 48-49, 50-51, 77, 291  
PENTALYSE, 43-46, 46  
PENTAMAKS, 40  
PENTATHLON, 40  
PENTHIFRA, 40  
direct thrombin inhibitors, 36t, 38t, 47-54  
argatroban, 38t, 53  
bivalirudin, 38t, 47, 52-53  
dabigatran etexilate, 53-54  
desirudin, 36t, 38t, 47  
hirudins, 47-53  
lepirudin, 38t, 47, 52  
melagatran, 53  
ximelagatran, 53  
heparins, 33-37  
LMWH, 34-37  
UFH, 33-34  
oral, 335  
in PCI, 294-295  
selective factor Xa inhibitors, 36t, 37-47, 37t  
fondaparinux, 36t, 37-47, 37t, 38t, 40, 42, 43, 44-45  
rivaroxaban, 348, 349-351, 351t, 361-362  
under development, 57  
warfarin, 54-57
- Antithrombotic therapy, 33-63. See also *specific topics and agents*.  
ACCP, AHA, and ESO guidelines for stroke, 312t-313t  
antiplatelet agents, 188  
aspirin, 83-113  
clopidogrel, 131-150  
GP IIb/IIIa receptor antagonists, 161-181  
ticlopidine, 115-130  
clinical syndromes (arterial and venous diseases). See *Clinical syndromes*.  
clotting factors and roles, 15-23, 16t

Antithrombotic therapy (*continued*)

combination therapy. See *Combination therapy*.  
complications of. See *Complications of antithrombotic therapy*.  
fibrinolytic agents, 65-82  
    adjunctive therapy for, 76-77  
    monitoring, 355-357  
    anticoagulant monitoring, 231-238  
    platelet function testing, 183-194  
periprocedural management, 206, 206t  
plasminogen activators, 65-82  
thrombosis physiology, 15-23  
    platelet roles, 25-29  
    in TIAs and stroke, 309, 312t-315t  
    timing in, 77-79, 357, 358  
    transitioning between agents, 359  
Antithyroid drugs, 395t  
Anti-Xa agents, 348, 359  
Anti-Xa assay, 234-236  
Anti-Xa levels, not predicative of bleeding risk, 400t  
Aortic insufficiency, 327  
Aortic valve, 328, 330. See also *Valvular heart disease*.  
APC. See *Activated protein C (APC)*.  
Apixaban, 348  
APRICOT-2 trial, 297t  
APSAC (anisoylated plasminogen-streptokinase activator complex; anistreplase), 68t, 70-71, 71, 407  
APTT (activated partial thromboplastin time), 33, 34, 232-233, 235t  
Arachidonic acid (AA), 96, 104, 188  
    ASA response variability and, 101, 198  
    platelet activation and, 103, 184, 189  
    ticlopidine and, 115  
ARBs, 316t  
Argatroban, 38t, 53  
    complications of, 405  
    dosage, 402t  
    in HIT, 402, 402t, 403  
    monitoring, 231, 236, 236t, 402t  
    prothrombin time, effect on, 232  
Arrhythmia. See *Atrial fibrillation (AF)*.  
Arterial and venous diseases. See *Clinical syndromes*.  
Arterial dissection, 315t  
ASPECT-2 trial, 296t, 297t  
Aspirin, 83-113, 188. See also *Antiplatelet agents*.  
    acquired platelet defects and, 188t  
    ACS and, 87, 249, 254t, 258  
    action mechanisms, 83, 101, 108  
    administration (ASA) in clinical practice, 85, 85  
    ADP and, 83, 97  
    advantages/efficacy of, 83  
    adverse effects, 84  
        bleeding, 84, 86, 94t-95t, 96t  
    AF and, 354, 356t  
    allergy to, 91, 265, 318, 319t  
    AMI and, 275-276, 276, 294

Aspirin (*continued*)

    benefits of, 83, 108  
    based on vascular risk, 85, 85  
    clinical trials and research studies  
        Antiplatelet Trialists Collaboration, 86-87, 310-311t, 319  
        CAST, 310t  
        CHARISMA, 87, 133-135, 137, 138t, 198  
        Chinese Stroke Trial, 91  
        CURRENT-OASIS-7, 87, 144-145  
        ESPRIT, 310t  
        ESPS-2, 310t  
        HOPE, 96, 102t, 198  
        International Stroke Trial, 91  
    primary prevention of vascular events, 85-86, 88-89, 92-93, 94t-95t, 96t  
    secondary prevention of vascular events, 86, 98-100  
combination therapy  
    with clopidogrel, 91, 144, 147, 249, 275, 318t, 322t  
    with dipyridamole, 91, 318t-319t  
    with fibrinolytic agents, 76  
    with ibuprofen, 95  
    with other antiplatelet agents, 87  
    with streptokinase (SK), 70  
    with ticagrelor, 91  
triple antithrombotic therapy, 204-206  
    with UFH, 249  
    with warfarin, 324, 354  
coronary artery bypass grafting (CABG) and, 87-91  
COX inhibition by, 83, 84, 97  
desensitization to, 91  
dosing, 86-87, 101  
    in AMI, 275-276  
    in diabetic patients, 84  
drug interaction with heparins, 35  
enteric-coated preparations, 83-84  
high-on treatment reactivity, 101-105, 103, 104  
ischemic stroke and, 91, 308  
PAD and, 307-308, 319-322, 320t-321t, 324  
PCI and, 91  
pharmacokinetics and pharmacodynamics, 83-84, 101  
"resistance" to. See *Response variability, below*.  
response variability, 95-97, 198, 199t  
    acquired, 97  
    clinical impact of, 95-97  
    clinical studies of, 95, 102t, 105, 106t-107t  
    mechanisms of, 95, 101-105, 101, 103, 104  
    prevalence of true aspirin resistance, 105, 108  
    TXA<sub>2</sub> synthesis and, 95, 97  
    TXB<sub>2</sub> synthesis and, 96, 102t  
risk-based approaches for, 85, 85  
for stroke and TIAs, 91, 310-311t, 314t, 318t-319t, 324, 360-361  
titration and, 97  
tolerability, 84, 108  
in valvular heart disease/thrombosis, 336t-338t  
VerifyNow Aspirin Assay, 189  
vs clopidogrel, 91, 132-133, 134t, 135, 136, 354-355  
vs ticlopidine, 117, 121, 122t-124t, 125, 127t

ASSENT 2 and 3 trials, 73, 74, 76, 278, 285, 286  
 AT. See *Antithrombin (AT)*.  
 Atenolol, 56t  
 Atherosclerosis, thrombotic processes and, 307, 308, 324  
 ATRIA study, 352  
 Atrial fibrillation (AF), 343-364  
   antiplatelet agent roles in, 354-355  
   cerebral thromboembolism risk and, 343-346, 344, 345, 345t  
   clinical trials and research studies  
     ACTIVE-A, 354-355  
     ACTIVE-W, 354-355  
     AFASAK, 354  
     AFFIRM, 347-348  
     ATRIA, 352  
     Atrial Fibrillation Trialists, 346  
     EAFT, 354  
     RACE, 347-348  
     ROCKET-AF, 349-351, 351  
     SPAF, 232, 346, 354  
   echocardiography in, 346, 346t  
   future challenges, 356-358  
   outpatient anticoagulation, improving, 360, 360t, 361  
   prevalence and classification, 343, 361  
   rhythm and rate control, 347-348  
   stroke risk and, 343, 344, 345, 345t, 346t, 356t  
   therapy for, 346-357  
     alternative, nonpharmacologic approaches, 355  
     anticoagulation, risks vs benefits, 353, 355-357  
     antiplatelet agents, 351-354  
     aspirin and, 354, 356t  
     dabigatran etexilate, 53, 361-362  
     effectiveness of, 346-351  
     initiating and monitoring, 355-357, 356, 356t, 357, 358  
     recommendations for, 355t  
     rivaroxaban, 349-351, 351  
     therapeutic window, 357, 358  
     transitioning, 359  
     warfarin, 348, 351-352, 352t, 355, 356t, 396  
       risks and benefits, 351-354, 353, 353t, 396  
 ATTRACT trial, 382  
 Baker's cyst, 370  
 Balloon, intra-aortic, 248  
 Balloon angioplasty, 77, 91, 162, 291, 321t  
 Balloon valvotomy, 336t  
 Barbiturates, 56t, 395t  
 Bedside assays and instruments, 185-191  
   clot retraction assay, 185  
   PFA-100, 185  
   PlateletWorks Assay, 189  
   rapid platelet function assay, 188-189, 190, 191t, 198  
   thromboelastography, 189-191  
   VerifyNow Aspirin Assay, 189  
   VerifyNow P2Y<sub>12</sub> Assay, 189  
 Bernard-Soulier disease, 183, 186t  
 β-Blockers, 248, 253t  
 Binding proteins (BPs), 17, 28, 32  
 Bioamplification reactions, 331  
 Bivalirudin (Angiomax), 38t, 47, 52-53, 236  
   in ACSs, 252-258, 255t, 268t, 269t  
   complications of, 405  
 Bleeding, 391-413. See also *Complications of antithrombotic therapy*.  
   in AF, 352, 353, 353t  
   aspirin and, 84, 86, 94t-95t, 96t  
   clopidogrel and, 145  
   as contraindication to fibrinolytic therapy, 78  
   direct thrombin inhibitors and, 402t, 405-406  
   fibrinolytic agents and, 66, 70, 279, 406-407  
   fondaparinux and, 41-46, 42, 43, 44-45, 392t, 399, 401  
   GP IIb/IIIa receptor antagonists and, 165, 166  
   heparins and, 35, 398-400  
     management of, 401  
   INR and, 355, 357  
   intracranial hemorrhage, 57, 66, 73, 165, 279, 348, 353t, 354, 406  
   periprocedural management and risk assessment, 206, 206t, 207t  
   plasminogen activators and, 66  
   prasugrel and, 152-153, 154t-155t, 158-159, 249  
   risks  
     hemorrhagic risk scale, 334t  
     risk score, 399  
     summary of, 398-400  
     therapeutic window and, 357, 358  
   streptokinase and, 70  
   ticlopidine and, 116  
   unexplained, testing for, 183  
   warfarin and, 224, 352-354, 353, 353t, 358, 391-398, 392t  
     management of, 396-397  
 Bleeding time, 183  
 Blood flow, 18-20, 30-31  
 Bone formation, inhibition by heparins, 33-34  
 Bone loss, in pregnancy, 405  
 Bone marrow suppression, ticlopidine and, 116, 126  
 Bone marrow transplants, 221  
 BPs. See *Binding proteins (BPs)*.  
 Bridging therapy, 335  
 Bumetanide, 56t  
 Bypass grafts. See *Coronary artery bypass grafts (CABGs)*.  
 C4B-BP, 17, 221, 222  
 C677T polymorphism, 216  
 CABGs. See *Coronary artery bypass grafts (CABGs)*.  
 CADILLAC trial, 166  
 Calcium channel blockers, 248, 253t  
 CAPRIE trial, 132-133, 134t, 135, 136, 276-277, 310t  
 CAPTURE study, 162  
 Carbamazepine, 56t, 395t  
 Cardiac biomarkers, 258  
 Cardiac drugs, 56t, 394, 395t  
 Cardiac events, major adverse (MACE), 196, 201  
 Cardioembolism, 307, 314t-315t, 343  
 Carotid endarterectomy, 97, 308  
 CARS study, 295, 296t, 297t

CAST, 310t  
 Catecholamine-mediated platelet activation, 105  
 CATS, 118t, 125, 310t  
 Cell-based coagulation model, 27-28, 28, 30-31  
 Cellulitis, 368  
 Central nervous system (CNS) agents, 394, 395t  
 Cerebral thromboembolism risks, 343-346, 344, 345, 345t  
 Cerebral thrombosis, 219  
 Cerebral venous sinus thrombosis, 315t  
 Cerebrovascular disease, 308-309, 310t-317t  
 CHADS2 score, 204, 346, 347t, 361  
 CHAMP study, 296t, 297t  
 CHAMPION-PCI, 144  
 CHAMPION-PLATFORM, 144  
 CHARISMA study, 87, 133-135, 137, 138t, 198  
 CHEST 2008 summary of recommendations, 356t, 360-361  
 Chinese Stroke Trial, 91  
 Chlordiazepoxide, 56t, 395t  
 Cholesterol, 316t-317t  
 Cholestyramine, 56t, 394, 395t  
 Chronic thromboembolic pulmonary hypertension (CTPH), 383  
 Cilostazol, 188, 188t, 317, 320t  
 Cimetidine, 56t, 395t  
 Ciprofloxacin, 395t  
 CLARITY-TIMI trial, 76, 144  
 CLARITY trial, 277, 287, 288  
 CLASSICS, 135-136  
 Claudication, 118t, 121, 125, 309, 320t, 324  
 CLEAR-PLATELETS study, 200  
 Clinical syndromes (arterial and venous diseases). See also *specific topics*.  
   acute coronary syndromes, 239-273  
   acute myocardial infarction, 275-306  
   atrial fibrillation, 343-364  
   peripheral arterial vascular disease and stroke, 307-326  
   valvular heart disease, native and prosthetic, 327-341  
   venous thromboembolic disease and PE, 365-390  
 Clinical trials and research studies  
   ACTIVE-A, 354-355  
   ACTIVE-W, 354-355  
   ACUITY, 258  
   ADMIRAL, 165, 166  
   AFASAK, 354  
   AFFIRM, 347-348  
   ALBION, 140  
   Antiplatelet Trialists Collaboration, 86-87, 307, 319  
   APRICOT-2, 296t, 297t  
   ASPECT-2, 296t, 297t  
   ASSENT 2 and 3, 73, 74, 76, 278, 285, 286  
   ATRIA, 352  
   Atrial Fibrillation Trialists, 346  
   ATTRACT, 382  
   CADILLAC, 166  
   CAPRIE, 132-133, 134t, 135, 136, 276-277, 310t  
   CAPTURE, 162  
   CARS, 295, 296t, 297t  
   CAST, 310t  
   Clinical trials and research studies (*continued*)  
   CATS, 118t, 125, 310t  
   CHAMP, 296t, 297t  
   CHAMPION-PCI, 144  
   CHAMPION-PLATFORM, 144  
   CHARISMA, 87, 133-135, 137, 138t, 198  
   Chinese Stroke Trial, 91  
   CLARITY, 277, 287, 288  
   CLARITY-TIMI, 76, 144  
   CLASSICS, 135-136  
   CLEAR-PLATELETS, 200  
   COBALT, 281t  
   COMMIT, 144, 287  
   COMMIT/CCS-2, 76, 277  
   CREDO, 140-144  
   CURE, 140, 141, 142-143, 145, 249, 277  
   CURRENT-OASIS-7, 87, 144-145  
   DANTE, 201  
   EAFT, 354  
   EARLY-ACS, 178  
   EMATAP, 118t  
   EPHESUS, 40  
   EPIC, 162, 164t  
   EPILOG, 162  
   EPISTENT, 116, 121  
   ESPRIT, 172, 310t  
   ESPS-2, 310t  
   ESSENCE, 251  
   EXPERT, 39, 40  
   ExTRACT-TIMI, 76-77, 289-291, 290  
   FANTASTIC, 121  
   Fibrinolytic Therapy Trialists, 279  
   GISSI, 70  
   GISSI-2, 278  
   GRAVITAS, 201  
   GUSTO, 69-70, 73-75, 74, 76, 278  
   GUSTO I, 278, 280t, 282  
   GUSTO IV-ACS, 162-165  
   GUSTO V, 165, 285, 286  
   HOPE, 96, 102t, 198  
   HORIZONS, 295  
   IMPACT-AMI, 169  
   IMPACT-II, 169  
   INJECT, 73, 280t  
   International Stroke Trial, 91  
   International Study Group, 280t  
   InTime-2, 75  
   INTRO-AMI, 284  
   ISAR-CHOICE, 140  
   ISAR-REACT, 140  
   ISAR-REBOUND/ISAR-CAUTION, 196  
   ISAR-SAFE, 196  
   ISAR-TRIPLE, 206  
   ISIS-2 and -3, 70, 71, 280t  
   IST, 91, 311t  
   MATISSE, 39-41

Clinical trials and research studies (*continued*)

MATTIS, 121  
NICE, 289  
OASIS, 41-47, 42, 43, 44-45, 48-49, 50-51, 77, 87, 251, 291  
PCI-CLARITY, 287, 288  
PCI-CURE, 136, 139  
PENTALYSE, 43-46, 46  
PENTAMAKS, 40  
PENTATHLON, 40  
PENTHIFRA, 40  
Phase 4, 57  
PLATO, 295  
PREMIER, 195  
PREPARE POST-STENTING, 201  
PREVENT, 379  
PRISM, 167, 170t-171t  
PRISM-Plus, 167-168, 170t-171t  
PROFESS, 311t  
PROLONG, 379  
PURSUIT, 169, 172  
RACE, 347-348  
RAPPORT, 166  
RE-LY, 349, 350  
REPLACE 2, 258  
RESTORE, 167, 175  
ROCKET-AF, 349-351, 351  
SALT, 311t  
SPAF, 232, 346, 354  
SPEED, 285  
STIMS, 118t  
Swedish Ticlopidine Multicenter Study, 125  
TACTICS-TIMI, 168  
TARGET, 136-137, 175, 176t  
TASS, 118t, 125-126, 311t  
TIMI trials, 168, 249, 251, 284-285, 285  
TISS, 118t  
TMD, 119t  
TRITON, 145, 152-153, 154t-155t, 156, 158-159, 294  
TRITON-TIMI38, 249  
UK-TIA, 311t  
WARIS, 295, 296t, 297t  
WOEST, 206  
Clofibrate, 56t, 395t  
Clopidogrel (Plavix), 131-150, 188. See also *Antiplatelet agents*.  
absorption of, 132  
acquired platelet defects and, 188t  
in ACSs, 249, 256t-257t  
action mechanism, 131  
in AF, 354-355  
in AMI, 276-277  
benefits of, 126, 131, 147  
clinical experience, 132-135  
acute coronary syndromes, 140-145, 249, 254t  
coronary stenting, 135-140  
dosing, 140  
primary prevention evaluations, 132-135

Clopidogrel (Plavix) (*continued*)

clinical trials  
ALBION, 140  
CAPRIE, 132-133, 134t, 135, 136, 276-277, 310t  
CHAMPION-PCI, 144  
CHAMPION-PLATFORM, 144  
CHARISMA, 133-135, 137, 138t  
CLARITY-TIMI, 76, 144  
CLASSICS, 135-136  
COMMIT, 144  
CREDO, 140-144  
CURE, 140, 141, 142-143, 145  
CURRENT-OASIS-7, 144-145  
ISAR-CHOICE, 140  
ISAR-REACT, 140  
PCI-CLARITY, 287, 288  
PCI-CURE, 136, 139  
TARGET, 136-137  
TRITON, 145, 154t-155t  
combination therapy  
with aspirin, 91, 144, 147, 249, 275, 318t, 322t  
fibrinolytic agents, 76, 144, 275-277  
triple antithrombotic therapy, 204-206  
dosing, 140, 144-145, 201  
drug interactions, 147  
effects on platelets, *in vitro* and *ex vivo*, 131, 131  
hemorrhagic risk minimization, 145  
indications, 131, 354-355  
pharmacodynamics, PPIs and, 147  
pharmacogenetics, 145, 146  
as prodrug, 145, 147  
response variability, 200-201, 202t-203t  
safety, 132, 145, 146  
vs efficacy, balance of, 256t-257t  
in stroke, TIAs and PAD, 310t, 314t, 318t-319t, 320t, 322, 324  
TTP and, 132  
vs aspirin, 132-133, 134t, 135, 136, 354-355  
vs prasugrel, 154t-155t  
vs ticlopidine, 116, 126, 132  
Clot retraction assay, 185  
Clotting factor concentrates, 396  
Clotting factor roles and fibrinolysis, 15-23, 16t  
activation/initiation events for, 15-16, 17, 25-27  
fibrin generation, 17-18, 19  
fibrinolysis, 18, 19, 65, 66. See also *Fibrinolytic agents*.  
 $\alpha_2$  antiplasmin and, 18, 19  
endogenous, 19, 275  
endogenous plasminogen activators, 65, 66  
PAI-1 and, 18, 19  
TAFI and, 18  
tPA and, 18, 19, 65-66, 67  
inactivation of. See *Antithrombotic agents*.  
initiation of thrombosis, 15-16, 17  
platelet binding proteins, 32

Clotting factor roles and fibrinolysis (*continued*)

procoagulant and anticoagulant factors, 16t. See also *specific factors*.  
  acarboxylated form of, 54  
  antithrombin, 16t  
  APC, 17, 18  
  factors V through XIII, 15-17, 16t, 17. See also *specific factors*.  
  fibrinogen, 16t  
  gene mutations, 214t, 215  
  GP IIa/IIIb and, 16  
  half-life chart for, 16t  
  HMWK and, 15  
  microparticles and, 16  
  P-selectin and, 15  
  prekallikrein (PK), 15, 18  
  proteins C and S, 16t, 17  
  prothrombin, 16, 16t  
  TFPI and, 15, 16t, 17  
  tissue factor (TF), 15, 17  
  TM and, 16-17, 18  
  vitamin K and, 54  
  vWF, 17, 20  
  statins and, 20, 21  
  thrombin generation/regulation, 16-17, 18t, 27  
  vascular factors, 18-20  
CNS agents, 394, 395t  
CoaguChek, 360  
Coagulation. See also *Anticoagulants*.  
  cell-based model of, 27-28, 28, 30-31  
  platelet support of, 27-28, 28  
  process of, 15-23, 17t. See also *Clotting factor roles and fibrinolysis*.  
  stages in, 27-28, 28  
COBALT trial, 281t  
Collagen, 16, 25, 83, 97, 103  
  platelet sensitivity to, 105  
Combination therapy. See also *specific agents*.  
  dual antiplatelet therapy, 196, 201  
  quadruple antithrombotic therapy, 205  
  triple antithrombotic therapy, 204-206  
COMMIT, 144  
COMMIT/CCS-2, 76, 277  
Complement, 17, 115  
Complications of antithrombotic therapy, 391-413, 392t. See also *Bleeding*.  
  direct thrombin inhibitors, 402t, 405-406  
  fibrinolytic agents, 392t, 406-407  
    bleeding, 406  
    delayed lysis, 406  
    reocclusion, 69, 406-407  
    SK therapy, 407  
  heparins, 392t, 398-405  
    bleeding, 398-400  
      management of, 401  
    eosinophilia, 392t, 404  
    HIT and, 34, 35, 401-403, 402t  
    HITTS and, 401  
    hyperkalemia, 404  
    hypoaldosteronism, 404

Complications of antithrombotic therapy, heparins (*continued*)

  hypotension, 404  
  LMWH, 398-399, 400t  
  osteoporosis, 309t, 404  
  pregnancy and, 404-405  
  thrombocytopenia, 35, 392t  
  UFH, 399-400  
venous thromboembolic disease and pulmonary embolism, 380-384  
  CTPH, 383  
  DVT, 380-384  
  PE, 382-383, 383t  
  postphlebotic syndrome, 278-280  
  vena cava filters, 384  
  warfarin, 391-398, 392t  
    adverse reactions other than bleeding, 397-398  
    age/gender factors, 393-394  
    changes and duration of treatment, 395-396  
    diet and, 394  
    drug interactions, 394, 395t  
    genetic factors, 393  
    hemorrhage/bleeding, 391-394, 393t  
    management of, 396-397  
    risk factors, 393-395, 393t  
Congenital disorders of platelet function, 184, 186t-187t  
Congestive heart failure, 140, 287, 343, 346, 373  
Contact activation system, 15, 18, 28  
Contraceptives, oral, 214t, 220t, 221, 223  
Coronary arterial stenting, 77. See also *Stents*.  
  clopidogrel and, 135-140, 145, 146  
  ticlopidine and, 121, 125  
Coronary artery bypass grafts (CABGs)  
  aspirin resistance and, 97  
  aspirin therapy and, 87-91  
  clopidogrel and, 145  
  CURE trial and, 145  
  ticlopidine and, 117-121  
Coronary artery disease, 239, 241-243. See also *Acute coronary syndromes (ACSs)*.  
  coexistence with PAD, 307  
  periprocedural management of antiplatelet therapy, 206, 206t  
  ticlopidine and, 117, 121  
Coronary events, aspirin and prevention of, 85-86, 92-93, 96t  
Co-trimoxazole, 56t, 395t  
Coumadin. See *Warfarin (Coumadin)*.  
Coumarins, 54. See also *Warfarin (Coumadin)*.  
COX (cyclooxygenase)-1 and -2 inhibition mechanisms, 188  
  aspirin and, 83, 84, 97  
Creatine clearance (CrCl), 35, 359  
CREDO trial, 140-144  
CRUSADE Registry, 204  
CTPH (chronic thromboembolic pulmonary hypertension), 383  
CURE trial, 140, 141, 142-143, 145, 249, 277  
Cyclooxygenase-1 and -2. See *COX-1 and -2*.  
CYP2C9 enzyme, 54, 376  
  clopidogrel and, 145  
  polymorphisms in, 54, 145, 152  
  prasugrel and, 152  
  warfarin and, 393

- Cytochrome P450 system, 54, 145, 151, 393
- D-dimer, 19, 370, 371, 371, 372, 372, 379, 380
- Dabigatran etexilate, 53-54, 236, 361-362  
 in AF, 349, 361-362  
 cessation before surgery, and starting after, 359  
 complications of, 405-406  
 RE-LY trial, 349, 350  
 transitioning from warfarin/heparins to, 359
- Dalteparin (Fragmin), 36, 36t, 400  
 in ACSs, 255t  
 dose and indications, 37t  
 in DVT, 375, 375t
- DANTE trial, 201
- Deep vein thrombosis (DVT). See also *Venous thromboembolic disease and pulmonary embolism*.  
 complications of, 380-384  
 diagnosis, 367, 371  
 incidence, 365  
 laboratory testing for, 370-372, 371  
 outpatient therapy, 376-377  
 scoring system, 368, 369t  
 signs and symptoms, 368, 369t  
 thrombophilia and, 213  
 treatments for, 37t, 374-376  
   duration of treatment, 377-379  
   fondaparinux, 37t, 373-374, 375t  
   heparins, 35, 37t, 374-375, 375t  
   idaraparinux, 57
- Delayed lysis, 406
- Dermatan sulfate, 20
- Desirudin (Iprivask), 36t, 38t, 47, 52  
 complications of, 405  
 in HIT, 402, 402t, 403  
   dosage and monitoring, 402t  
   for VTE prophylaxis, 374
- Dextran, 321t
- Diabetes mellitus, 84, 316t
- Diabetic retinopathy, ticlopidine in, 119t
- Diet, 394
- Diflunisal, 56t
- Dilated cardiomyopathy, 333t
- Dipyridamole, 91, 310t, 311t, 313t, 318t-319t
- Direct thrombin inhibitors, 36t, 38t, 47-54. See also *Antithrombotic agents; specific agents*.  
 in ACSs, 252-258  
 in AF, 348-349, 361  
 argatroban, 38t, 53, 236, 236t  
 complications of, 402t, 405-406  
 dabigatran etexilate, 53, 349  
 hirudins, 47-53  
   bivalirudin, 38t, 47, 52-53, 236  
   desirudin, 36t, 38t, 47, 52, 236  
   lepirudin, 38t, 47, 52, 236, 236t  
 in HIT, 402, 402t  
 indications for, 36t, 52, 53
- Direct thrombin inhibitors (*continued*)  
 melagatran, 53  
 monitoring, 231, 236, 236t, 402t  
 oral, 361-362  
 prothrombin time, effect on, 232  
 structure/actions of, 47-52  
 ximelagatran, 53
- Drug interactions  
 aspirin, 35  
 clopidogrel, 147  
 heparins, 35  
 ticlopidine, 116  
 warfarin, 55, 56t, 394, 395t
- Duteplase, 280t
- DVT. See *Deep vein thrombosis (DVT)*.
- EAFT trial, 354
- EARLY-ACS trial, 178
- Ecarin clotting time (ECT), 359
- Echocardiography, 346, 346t
- ECT (ecarin clotting time), 359
- Eczematous plaques, 404
- Edoxaban, 57, 348
- Effient. See *Prasugrel (Effient)*.
- Elderly patients, 205, 373  
 antiphospholipid antibodies in, 221  
 drug dosage and half-lives in, 39, 132, 349, 375, 376, 396  
 heparins in, 399, 400  
 warfarin in, 351, 355, 356, 396, 398
- Electrical cardioversion, 347
- Electrocardiogram (ECG)  
 in ACSs, 241, 242t, 243t, 244-247  
 in AMI, 275
- EMATAP study, 118t
- Endarterectomy, carotid, 97, 308
- Endogenous fibrinolysis, 19, 275
- Endothelial cells, 30-31, 328  
 ticlopidine effects on, 115
- Endothelium-derived factors, 21
- Endotoxemia, 214t
- Enoxacin, 56t
- Enoxaparin (Lovenox), 36, 36t, 37t, 400  
 in ACSs, 255t, 269t  
 in AMI, 76-77, 289-291, 290  
 in combination with fibrinolytics, 76-77  
 dose and indications, 37t  
 in DVT, 374, 375t  
 in pregnancy, 405  
 in valvular heart disease/thrombosis, 335, 405  
 vs desirudin, 52  
 vs fondaparinux, 39-43, 42, 43, 44-45
- Eosinophilia, 392t, 404
- EPHESUS trial, 40
- EPIC study, 162, 164t
- Epidural bleeding, 35, 400
- EPILOG study, 162

EPISTENT trial, 116, 121  
 EPRI, 32  
 Eptifibatid (Integrilin), 168-172, 188. See also *Glycoprotein IIb/IIIa receptor antagonists*.  
   in ACSs, 254t  
   clinical trials and experience, 169-172, 172  
   distinguishing characteristics, 172-174, 173t, 174, 175  
   pharmacodynamics, 168-169  
   pharmacokinetics, 168  
 Erythrocyte-mediated platelet activation, 105  
 Erythromycin, 56t, 395t  
 ESC guidelines, 267t, 268t  
 ESPRIT, 172, 310t  
 ESPS-2, 310t  
 ESSENCE trial, 251  
 Estrogens, thrombophilia and, 214t, 220t, 221  
 EXPERT study, 39, 40  
 ExTRACT-TIMI study, 76-77, 289-291, 290

Factor V, 16, 16t  
 Factor V Leiden. See *FVL (factor V Leiden)*.  
 Factor Va, 16, 32  
 Factor VII, 15, 16t, 20  
 Factor VIIa, 15, 17  
   recombinant (NovoSeven), 57, 396, 401  
 Factor VIII, 16t, 17  
   increased, 214, 214t, 215, 215t, 218, 221  
 Factor VIIIa, 16, 32  
 Factor IX, 15, 16t, 17  
   increased, 214t, 218  
 Factor IXa, 15, 17  
 Factor IX Padua, 218  
 Factor X, 15, 16t, 17  
   increased, 214t  
 Factor Xa, 15, 17, 32. See also *Anti-Xa*.  
   anti-Xa assay, 234-236  
   heparin inactivation of, 33, 34  
   inhibitors of, 36t, 37-47, 57, 335, 361-362  
   rivaroxaban, 349-351  
   synthetic, selective (fondaparinux), 36t, 37-47, 37t, 38t  
   plasmin and, 406  
   TFPI complex with, 15, 17  
 Factor XI, 15, 16t, 17, 32  
   increased, 214t, 218  
 Factor XIa, 15, 17  
 Factor XII, 15  
 Factor XIII, 16t  
 Factor XIIIa, 18  
 Factors, procoagulant and anticoagulant, 15-17, 16t. See also *specific factors*.  
 Famotidine, 56t  
 FANTASTIC trial, 121  
 Felodipine, 56t  
 Femoral vessel catheterization, 35  
 Fetal embryopathy, 55  
 Fibrillation, atrial. See *Atrial fibrillation (AF)*.  
 Fibrin, 66  
   cross-linked, 18, 21  
   generation of, 17-18, 19  
 Fibrin-bound thrombin, 33, 38t, 47  
 Fibrinogen, 16t, 17-18, 27, 32  
   binding, ticlopidine effect on, 115  
   gene mutations, 214t, 215  
   supplementation, GP IIa/IIIb receptor antagonists and, 174, 175  
   in thrombolytic pathway, 66  
 Fibrinolysis, 18, 19, 381. See also *Clotting factor roles and fibrinolysis*.  
   clot selectiveness of, 65, 283  
   endogenous, 19, 275  
   overview of, 65, 66  
 Fibrinolytic agents, 65-82. See also *Plasminogen activators*.  
   in ACSs, contraindication/caution for, 258  
   adjunctive antithrombotic therapy, 76-77  
   abciximab, 75, 76  
   ACC/AHA guidelines, 76  
   aspirin, 76  
   bleeding and, 76  
   clopidogrel, 76  
   enoxaparin, 75, 76-77  
   fondaparinux, 77  
   GP IIb/IIIa receptor inhibitors, 76  
   heparins, 75, 76-77  
   in AMI, 277-282, 282, 283-287, 285, 290t-291t  
   complications of, 279  
   mortality outcomes in, 280t-281t  
   recommendations for, 279-282, 283t  
   angioplasty vs, 77-79  
   APSAC (anistreplase), 68t, 70-71, 71  
   clinical features of, 68t  
   clinical trials and research studies, 69-70, 73-75, 74, 76-77  
   ASSENT 2 and 3, 73, 74, 76, 285, 286  
   CLARITY-TIMI, 76  
   COMMIT/CCS-2, 76, 287  
   ExTRACT-TIMI, 76-77  
   Fibrinolytic Therapy Trialists, 279  
   GISSI, 70, 278, 280t  
   GUSTO, 69-70, 73-75, 74, 76, 285, 286  
   INJECT, 73, 280t  
   International Study Group, 280t  
   InTime-2, 75  
   ISIS-2 and -3, 70, 71, 275, 280t  
   OASIS-6, 77, 291  
   complications of, 279, 392t  
   bleeding, 66, 70, 279, 406-407  
   delayed lysis, 406  
   reocclusion, 69, 406-407  
   contraindications and cautions, 78t  
   fibrin specificity of, 68t, 72t, 76  
   fibrinolytic system, overview, 65, 66  
   future development of, 79  
   GP IIb/IIIa receptor antagonists and, 165, 166  
   indications for, 65, 77-79  
   monitoring, 231, 236-237

- Fibrinolytic agents (*continued*)
- patient selection/assessment, 236-237
  - scu-PA, 65
  - streptokinase (SK), 68t, 69-70, 69
  - systemic effects of, 237
  - systemic lytic state, 65, 69, 75
  - third-generation, 71-76, 72t
  - third-generation fibrinolytics
    - clinical features of, 72t
    - GP IIb/IIIa and, 73
    - lanotriplase, 71, 72t, 75
    - PAI-1 resistance of, 71, 72t
    - properties of, 71
    - rPA (reteplase), 68t, 73, 74
    - saruplase (prourokinase), 71, 72t, 75
    - staphylokinase, 71, 72t, 76
    - TNK-tPA (tenecteplase), 68t, 73-75, 74
  - thrombolysis pathways and, 66
  - thrombolytic resistance and, 283-287, 284
  - tPA (tissue plasminogen activator), 18, 19, 65-66, 67
    - mutant forms of, 73-75
- Fibrinolytic system overview, 65, 66
- Fibrinolytic Therapy Trialists, 279
- Flow cytometry, 185
- Fluconazole, 56t, 395t
- Fluoxetine, 56t, 395t
- Fondaparinux (Arixtra), 37-47, 38t
  - in ACSs, 251-252, 255t, 268t, 269t
  - actions and structure of, 37-39, 38t
  - advantages of, 39, 47
  - in AMI, 291
  - clinical studies, 39-47, 77
    - EXPERT, 39
    - MATISSE, 39-41
    - OASIS-5, 41-43, 42, 43
      - subgroup analysis, 42-43, 44-45
    - OASIS-6, 46-47, 48-49
      - subgroup analysis, 47, 50-51
    - PENTALYSE, 43-46, 46
    - Phase 3 (PENTAMAKS, PENTHIFRA, PENTATHLON, EPHEBUS), 40
    - reocclusion rates, 46, 46
  - complications of (bleeding), 41-46, 42, 43, 44-45, 392t, 399, 401
  - dosage, 36t, 37t, 47, 269t
  - in DVT, 37t, 373-374, 375t
  - half-life, 39, 252
  - indications for, 36t, 37t, 39, 77
  - monitoring, 234-236
  - osteoporosis, reduced risk with, 404
  - physiology/metabolism, 39
  - in pregnancy, 405
  - properties of, 38t
  - renal impairment and, 39, 400
  - vs enoxaparin, 39-43, 42, 43, 44-45
  - for VTE prophylaxis, 373, 374
- Fragmin. See *Dalteparin (Fragmin)*.
- FURY mnemonic, 222, 223t
- FVL (factor V Leiden), 214, 214t, 215, 218, 219, 374
  - description of, 215-216
- Gangrene
  - limb, 55, 309, 317, 323t
    - warfarin and, 55, 403, 404
  - venous, 399, 403
- Gemfibrozil, 316t
- Gender factors, 393-394
- Genetic factors, warfarin and, 393
- Genetic platelet disorders, 184, 186t-187t
- Ginkgo, 55, 394
- Ginseng, 55, 394
- GISSI and GISSI-2 trial, 70, 278
- Glanzmann's thrombasthenia, 183, 186t
- Glycoprotein (GP) Ia, 219
- Glycoprotein (GP) Ib, 16, 25, 32
- Glycoprotein (GP) IIb/IIIa, 16, 27, 32, 219
  - deficiency of, 186t
  - IIIa $\beta_3$  gene mutations, 214t, 219
  - receptor, 161
- Glycoprotein IIb/IIIa receptor antagonists, 161-181, 188. See also *Antiplatelet agents*.
- acquired platelet defects and, 188t
- in ACSs, 249, 258
- adjunctive therapy with fibrinolytics, 76
  - adverse effects of, 77
- administration strategies, 177-178
  - bolus-only, 177
  - early administration, 178
  - intracoronary administration, 177
- in AMI, 294
- clinical experience
  - abciximab, 162-165, 164t, 166
  - eptifibatid, 169-172, 172
  - tirofiban, 167-170, 170t-171t
- clinical trials and research studies
  - ADMIRAL, 165, 166
  - CAPTURE, 162
  - death, reinfarction, and urgent TVR in, 165, 166
  - EARLY-ACS, 178
  - EPIC, 162, 164t
  - EPILOG, 162
  - ESPRIT, 172
  - GUSTO IV-ACS, 162-165
  - GUSTO V, 165, 285, 286
  - IMPACT-AMI, 169
  - IMPACT-II, 169
  - PRISM and PRISM-Plus, 167-168, 170t-171t
  - PURSUIT, 169, 172
  - RESTORE, 167, 175
  - TACTICS-TIMI, 168
  - TARGET, 136-137, 175, 176t
- clopidogrel and, 131
- discontinuation of, platelet aggregability after, 174, 174
- fibrinogen supplementation and, 174, 175

Glycoprotein IIb/IIIa receptor antagonists (*continued*)

- fibrinolytics and, 76-77, 165, 166
- half-lives, 161, 168, 173t
- intravenous (IV). See also *specific agents*.
  - abciximab, 161-165
  - clinical endpoints, 175, 176t
  - distinguishing characteristics, 172-174, 173t, 174, 175
  - eptifibatide, 168-172
  - tirofiban, 165-168
- monitoring response to, 189, 190
- pharmacodynamics, 161-162, 167, 168-169
- thrombocytopenia and, 165, 166, 177

GP. See *Glycoprotein (GP)*.

GP receptor antagonists. See *Glycoprotein IIb/IIIa receptor antagonists*.

GRACE Registry, 204-205

GRACE risk scores, 242, 250t-251t, 252

Grafts, bypass. See *Coronary artery bypass grafts (CABGs)*.

GRAVITAS trial, 201

Griseofulvin, 56t, 395t

GUSTO trials, 69-70, 73-75, 74, 76, 278

GUSTO I, 278, 280t, 282

GUSTO III, 280t

GUSTO IV-ACS, 162-165

GUSTO V, 165, 285, 286

H<sub>2</sub> antagonists, 84

Heart valves. See *Valvular heart disease*.

*Helicobacter pylori*, 84

Hematoma, 35, 52, 234, 368, 395, 400, 406

Hemorrhage. See *Bleeding*.

Hemostatic balance, 15

Hemostatic potential, assessing, 183

Heparin cofactor II, 214t, 218

Heparin-induced platelet antibodies, 403

Heparin-induced thrombocytopenia (HIT), 34, 35, 214t, 401-403

anticoagulant therapy in, 402t

diagnosis of, 401

localized form of, 403

management of, 52, 402-403, 402t

warfarin and, 55, 397-398

Heparin-induced thrombocytopenia with thrombosis (HITTS), 401

Heparins, 33-37. See also *Antithrombotic agents*.

ACSs and, 249-251, 255t, 268t, 269t

actions of, 33-34

advantages of new, 37

adverse effects, 35

AMI and, 282-291, 289t, 292-293

anti-Xa activity and, 33, 34

anticoagulant monitoring and, 33, 34-35, 402t

aPTT and, 33, 232-233, 235t

binding of cells/plasma proteins, 33

bone and, 33-34

chemical structure, 33

combination therapy

with aspirin, 249

with fibrinolytics, 75, 76-77, 275-277

Heparins (*continued*)

complications of, 35, 392t, 398-405

alopecia, 404

bleeding, 35, 392t, 398-400

antidote to, 35

management of, 401

eosinophilia, 392t, 404

HIT and, 34, 35, 401-403

HITTS and, 401

hyperkalemia, 404

hypoadosteronism, 404

hypotension, 404

LMWH, 35, 398-399, 400t

osteoporosis, 34, 309t, 404

pregnancy and, 34, 404-405

renal patients and, 34-35, 399-400

spinal subarachnoid hematoma, 400

thrombocytopenia, 35, 392t

UFH, 35, 399-400, 404

dosage, 33, 35, 36, 36t, 37t, 400

in ACSs, 269t

drug interactions, 35

DVT and, 37t, 374-375, 375t

half-life, 33, 34, 401

indications for, 36-37, 36t, 37t

high-risk patients, 70

thrombophilia, 223-224

LMWH (low molecular weight heparin), 34-37, 38t, 77

in ACSs, 251, 268t, 269t

in AMI, 289-291

complications of, 392t, 398-399, 404

for DVT, 35, 374, 375t

half-life, 34, 401

monitoring, 234-236

in PE, 383t

in pregnancy, 404

in stroke, 313t, 315t

use in surgery, guidelines for, 400t

in valvular heart disease/thrombosis, 334, 335, 337t-338t

VTE and, 373, 374, 379-380

monitoring, 33, 34-35, 231, 232-236, 235t

plasma levels, 34

porcine, 34

preparations/formulations, 35-36, 36t, 37t

dalteparin (Fragmin), 36, 36t, 37t

enoxaparin (Lovenox), 36, 36t, 37t

tinzaparin (Innohep), 36, 36t, 37t

properties of, 38t

rebound thrombin generation, 249

UFH (unfractionated heparin), 33-34, 38t

in ACSs, 249, 255t, 268t, 269t

in acute arterial insufficiency, 317-319

complications of, 399-400, 404

in DVT, 35, 374

half-life, 34, 399

in heart valve thrombosis, 334

Heparins, UFH (*continued*)  
 monitoring, 232-234, 235t, 249  
 in PE, 383t  
 in pregnancy, 404  
 in stroke and PAD, 313t, 315t, 320t-321t, 324  
 use with tPA, 66  
 in valvular heart disease/thrombosis, 334, 337t-338t

Herbal remedies, 55, 394

Hereditary platelet disorders, 184, 186t-187t

High molecular weight kininogen (HMWK), 15

Hip surgery  
 fondaparinux for, 39  
 heparins for, 36, 36t

Hirudins, 38t, 47-53  
 in ACSs, 252  
 actions of, 47-52  
 complications of, 405, 406  
 half-life, 52  
 indications for, 52  
 prothrombin time, effect on, 232  
 safety, 52  
 specific agents, 38t, 47, 52-53  
 bivalirudin, 38t, 47, 52-53  
 desirudin, 36t, 38t, 47, 52  
 lepirudin, 38t, 47, 52  
 structure/actions of, 47-52  
 thrombin and, 47-48

*Hirudo medicinalis*, 47

Hirulog. See *Bivalirudin*.

Histamine<sub>2</sub>-blockers, 84, 394, 395t

HIT. See *Heparin-induced thrombocytopenia (HIT)*.

HITTS. See *Heparin-induced thrombocytopenia with thrombosis (HITTS)*.

HMWK (high molecular weight kininogen), 15

Homans' sign, 368

Homocysteine. See *Hyperhomocysteinemia*.

HOPE trial, 96, 102t, 198

HORIZONS trial, 295

Hyperhomocysteinemia, 214t, 215, 216-217, 217t, 218

Hyperkalemia, 404

Hyperlipidemias, 214t

Hypertension, 78, 316t

Hypoaldosteronism, 392t, 404

Hypotension, 71, 279, 404, 407

Ibuprofen, 95

Idrabiotaparinux, 57

Idraparinix, 57

IMPACT-AMI trial, 169

IMPACT-II trial, 169

Impedance platelet aggregometry, 184

Indobufen, 118t

Infringuinal bypass, 321t

Inherited/acquired coagulation and platelet disorders, 213-230.  
 See also *Thrombophilia*.

Inherited platelet abnormalities, 184, 186t-187t

Inherited thrombophilia, 213-218, 214t

Initiation/activation events, 15-16, 17t

Initiation stage, 27, 28

INJECT trial, 73, 280t

Innohep. See *Tinzaparin (Innohep)*.

INR (international normalized ratio), 223-224, 231-232, 348  
 bleeding and, 355, 357, 391  
 level, in transitioning between agents, 359  
 target for, 358

Integrilin. See *Eptifibatide (Integrilin)*.

International normalized ratio. See *INR*.

International Sensitivity Index. See *ISI*.

International Stroke Trial, 91

International Study Group Trial, 280t

InTime-2 trial, 75

Intra-aortic balloon counterpulsation, 248

Intracranial hemorrhage, 57, 66, 73, 165, 279, 348, 353t, 355, 358, 406

INTRO-AMI trial, 284

Iprivask. See *Desirudin (Iprivask)*.

Irbesartan, 354

ISAR-CHOICE, 140

ISAR-REACT, 140

ISAR-REBOUND/ISAR-CAUTION, 196

ISAR-SAFE, 196

ISAR-TRIPLE, 206

Ischemia  
 limb. See *Limb ischemia*.  
 myocardial. See *Myocardial ischemia*.

Ischemic stroke, 308-309, 308  
 treatment/prevention of, 310t-317t

ISI (International Sensitivity Index), 54, 231

ISIS-2 and -3 trials, 70, 71, 275, 280t

Iso-TRAP, 188-189

Isoniazid, 56t, 395t

Isoprostane-mediated platelet activation, 105

IST (International Stroke Trial), 91, 311t

K, vitamin. See *Vitamin K*.

Ketorolac, 56t

Kidney impairment. See *Renal failure/impairment*.

L-Arginine, 53

Lanoteplase, 71, 72t, 75

Lepirudin (Refludan), 38t, 47, 52  
 in ACSs, 255t  
 complications of, 405  
 dosage, 402t, 405  
 for HIT, 402-403, 402t  
 monitoring, 231, 236, 236t, 402t

Leukocytes, 15, 28, 30-31

Light-transmission aggregometry, 184, 198

Limb ischemia, 309-317, 322t, 323t

Lipid-lowering agents, 253t

Lipoprotein a (Lp(a)), increased, 214t, 216

LMWH (low molecular weight heparin). See *Heparins*.

Lovastatin, 395t

Lovenox. See *Enoxaparin (Lovenox)*.

- Low molecular weight heparin (LMWH). See *Heparins*.
- Lupus anticoagulant (LA), 221, 222, 232, 374
- Lysis, delayed, 406
- Lysosomes, 27
- Lytic state, systemic, 65, 69, 75
- Macrophages, 15, 17
- MAST-1, 311t
- MATISSE study, 39-41
- MATTIS, 121
- Maze procedure, 355
- Melagatran, 53
- Methylenetetrahydrofolate reductase. See *MTHFR*.
- Metoprolol, 56t, 76, 144
- Metronidazole, 56t, 395t
- MI. See *Myocardial infarction (MI)*.
- Miconazole, 395t
- Microparticles, 16
- Mitral insufficiency, 327
- Mitral valve, 328, 331. See also *Valvular heart disease*.
- Monitoring, 231-238, 355-357. See also *specific agents*.
  - anticoagulants, 231-238, 355-357
    - direct thrombin inhibitors, 236, 236t
      - argatroban, 236, 236t
      - lepirudin, 236, 236t
    - fibrinolytic agents, 236-237
    - fondaparinux, 234-236
    - heparin therapy, 33, 34-35
    - heparins, 231, 232-236
      - LMWH, 234-236
      - UFH, 232-234, 235t
    - platelet function testing, 183-194
    - warfarin, 231-232, 355-357
- Monocytes, 15, 17
- MTHFR (methylene tetrahydrofolate reductase) gene mutations, 214t, 216, 218
- Myeloproliferative disorders, 188t, 214t
- Myocardial infarction (MI), 308. See also *Acute myocardial infarction (AMI)*;
  - STEMI (ST-segment elevation myocardial infarction)*; *Stroke*.
    - antithrombotic agents for, 37t
    - aspirin use for prevention, 85-86, 92-93, 275
    - clinical studies
      - CLARITY-TIMI, 76
      - COMMIT/CCS-2, 76, 144
      - ExTRACT-TIMI, 76-77, 289-291, 290
      - fondaparinux in, 43-47, 43, 46, 48-49, 50-51
      - tenecteplase in, 73, 74
    - clopidogrel for, 76, 131, 144
    - dabigatran and, 406
    - NSTEMI, 239-241, 240. See also *Acute coronary syndromes (ACSs)*.
    - pathobiology related to, 239-241, 240
    - prasugrel and, 152, 156, 158-159
    - reinfarction
      - abciximab and, 165, 166, 285
      - aspirin and, 275, 283, 297t, 298
      - clopidogrel and, 76, 144
      - enoxaparin and, 76-77, 291
- Myocardial infarction (MI), reinfarction (*continued*)
  - fibrinolytic therapies and, 279, 291
  - fondaparinux and, 41, 46-47, 77, 291
  - reteplase (rPA) and, 73, 285
  - UFH and, 47, 287, 291
  - warfarin and, 295, 297t, 298
  - risk scores/stratification, 242, 248t, 250t-251t, 252, 289t
  - STEMI, 240
  - thrombolysis in (TIMI), 41, 43, 66, 242, 248t, 250t, 252
  - ticlopidine for, 117
- Myocardial ischemia, 239-241, 240
  - algorithm for, 246-247
  - electrocardiogram, 241, 242t, 246-247
  - patient evaluation, 241-243, 242t, 244-247
    - early, 243t
  - refractory ischemia
    - abciximab and, 162
    - clopidogrel and, 140
    - enoxaparin and, 41-42, 42, 44-45, 251
    - fondaparinux and, 41-42, 42, 44-45, 251
    - GP IIb/IIIa receptor antagonists and, 167-168, 170t-171t, 178, 191t
    - reteplase (rPA) and, 74
    - tenecteplase (TNK-tPA) and, 74
    - tirofiban and, 167-168, 170t-171t
    - UFH and, 167
  - risk scores/stratification, 241-243, 248t, 250t-251t, 252
  - ST/T waves in, 244, 245
- Nafcillin, 56t, 395t
- Naproxen, 56t
- Native and prosthetic valvular heart disease. See *Valvular heart disease*.
- Necrosis, 55, 392t
- Nephrotic syndrome, 214t, 220t
- Neutrophils, 15, 17
- Niacin, 317t
- NICE trials, 289
- Nitrates, 248
- Nitrazepam, 56t
- Nitric oxide, 20, 216
- Nitroglycerin, 253t
- Non-CNS embolism, rivaroxaban and, 349-351, 351
- Noncardiac arterial disease. See *Peripheral arterial vascular disease and stroke*.
- Nonintracranial bleeding, 66, 351
- Nonsteroidal anti-inflammatory agents, 35, 52, 84
- Non-ST-segment elevation myocardial infarction. See *NSTEMI*
- NovoSeven, 396
- NSTEMI (non-ST-segment elevation myocardial infarction), 239-241, 240.
  - See also *Acute coronary syndromes (ACSs)*.
    - ACSs with, 239-273
    - defined, 275
    - early aggressive treatment approach, 259, 263t-269t
    - management of, summary, 260-262, 268t, 269t
    - patients with, 264-266t
    - revascularization in, 263t
    - TIMI risk score, 248t, 252
  - Number needed to treat, 351-352, 352t

OASIS studies, 41-47, 77, 251, 291  
 CURRENT-OASIS-7, 87, 144-145  
 OASIS-5, 41-43, 42, 43  
 subgroup analysis, 42-43, 44-45  
 OASIS-6, 46-47, 48-49  
 subgroup analysis, 47, 50-51

Occlusion, 64, 87, 117, 120t, 219, 222. See also *Reocclusion*.  
 acute arterial, 298, 317, 322t  
 causes of, 307  
 aspirin and, 199t, 283, 297t  
 bypass-related, 321t, 322  
 complete (in AMI), 275  
 device implantation for, 355  
 fibrinolytic therapy and, 277, 298, 319  
 HIT and, 401  
 nontraumatic, 317  
 partial (in NSTEMI), 275  
 peripheral arterial, 307, 322, 322t, 401  
 ticlopidine and, 121  
 venous, 367

Omeprazole, 56t, 395t

Orthopedic surgery  
 fondaparinux and other anticoagulants for, 39, 53  
 heparins for, 36, 36t  
 other anticoagulants for, 52-53, 57

Ossification, heterotopic, 368

Osteoporosis, 34, 392t, 404

Outpatient therapy, 360, 360t, 361  
 for DVT, 37t, 376-377  
 for MI, 243t, 247, 298  
 for PE, 382-383  
 warfarin, 354, 361

P2Y<sub>12</sub> inhibitors, 151  
 VerifyNow P2Y<sub>12</sub> Assay, 189

P450 detoxification system, 54, 145, 151, 393

PAD (peripheral artery disease), 309-317, 320t-321t, 322t, 323t.  
 See also *Peripheral arterial vascular disease and stroke*.  
 clopidogrel for, 131  
 ticlopidine and, 118t

PAI-1. See *Plasminogen activator inhibitor (PAI)-1*.

PAR1, 32

Patency enhancement strategies, 285

PCI-CLARITY trial, 287, 288

PCI-CURE study, 136, 139

PCI (percutaneous coronary intervention), 291-295  
 aspirin and, 91  
 clopidogrel and, 140-144  
 facilitated, fibrinolytic therapy and, 77-79  
 periprocedural management of antiplatelet therapy, 206, 206t  
 primary, 291-295  
 benefit from, 291-294  
 optimal antithrombotic agents for, 294-295  
 timing of, 291-294

PE. See *Pulmonary embolism (PE)*.

PENTALYSE study, 43-46, 46

PENTAMAKS trial, 40

Pentasaccharide  
 binding of antithrombin, heparins and, 33, 34  
 synthetic. See *Fondaparinux (Arixtra)*.

PENTATHLON trial, 40

PENTHIFRA trial, 40

Pentoxifylline, 320t

Percutaneous coronary intervention. See *PCI*.

Peripheral arterial vascular disease and stroke, 307-326  
 acute arterial insufficiency, 317-322  
 arterial beds frequently involved, 307  
 causes of acute occlusion, 307, 322t  
 cerebrovascular disease and stroke, 308-309, 310t-315t  
 clinical trials and research studies  
 CAPRIE, 310t  
 CAST, 310t  
 CATS, 118t, 125, 310t  
 ESPRIT, 310t  
 ESPS-2, 310t  
 IST, 91, 311t  
 MAST-1, 311t  
 TASS, 118t, 311t  
 UK-TIA, 311t  
 limb ischemia, 309-317, 322t, 323t  
 mortality from, 307  
 PAD, 309-317, 320t-323t  
 peripheral vascular reconstructive surgery, 322-324  
 recommendations for, 310t-315t, 320t-321t, 324  
 thrombotic processes in, 307, 308  
 ticlopidine and, 118t, 121-125  
 vascular disease, concepts, 307-308

Peripheral artery disease. See *PAD*.

Peripheral vascular disease. See *Peripheral arterial vascular disease and stroke*.

PFA (platelet function analyzer)-100, 105, 184, 185, 198

Phenylbutazone, 56t, 395t

Phlebitis, 365, 368, 379

Physiology of thrombosis, 15-23

Phytonadione, 55

Piroxicam, 56t, 395t

PK (prekallikrein), 15, 18

Plaque, 239-241, 240, 275

Plasma, 57, 174, 396-397

Plasmin, 18, 19, 66, 406  
 $\alpha_2$ -antiplasmin, 18, 19, 65, 66, 69  
 circulating inhibitors of, 65, 66

Plasminogen  
 conversion to plasmin, 65, 66, 67  
 gene mutations, 214t

Plasminogen activators, 65-82. See also *Fibrinolytic agents*.  
 adjunctive antithrombotic therapy, 76-77  
 clinical features of, 68t  
 contraindications and cautions for, 78t  
 endogenous, 65, 66  
 fibrin specificity of, 68t  
 fibrinolytic system overview, 65, 66  
 future development of, 79

Plasminogen activators (*continued*)

specific agents

- alteplase, 65-66
- APSAC (anistreplase), 68t, 70-71, 71
- scu-PA (single-chain urokinase plasminogen activator), 65
- SK (streptokinase), 68t, 69-70, 69
- tPA (tissue plasminogen activator), 18, 19, 65-66, 67, 68t
- third-generation fibrinolytics, 71-76, 72t
- lanoteplase, 71, 72t, 75
- PAI-1 resistance of, 71, 72t
- properties of, 72t
- rPA (reteplase), 68t, 73, 74
- saruplase (prourokinase), 71, 72t, 75
- staphylokinase, 71, 72t, 76
- TNK-tPA (tenecteplase), 68t, 73-75, 74

Plasminogen activator inhibitor (PAI)-1, 18, 19, 65

- increased, 214t
- resistance to, of newer fibrinolytics, 71, 72t

Platelet abnormalities

- acquired, 184, 188t, 188t
- hereditary, 184, 186t-187t
- in thrombophilia, 219

Platelet activation, 25-27, 284

- aspirin and, 83
- inhibition of. See *Antiplatelet agents*.
- intracellular and surface-based events in, 103
- non-COX-1 mediated pathways of, 101, 104

Platelet activity monitoring. See *Platelet function testing*.

Platelet aggregation, 27

- inhibition of. See *Antiplatelet agents; Glycoprotein IIb/IIIa receptor antagonists*.

Platelet antagonists. See *Antiplatelet agents; Glycoprotein IIb/IIIa receptor antagonists*.

Platelet binding proteins, 28, 32

Platelet factor 4, 33, 34

Platelet function score, 198

Platelet function testing, 183-194. See also *Platelet response variability*.

- adhesion tests, 184
- aggregometry, 105, 184
- bedside assays and instruments, 185-191
  - clot retraction assay, 185
  - PFA-100, 105
  - PlateletWorks Assay, 189
  - rapid platelet function assay, 188-189, 190, 191t, 198
  - thromboelastography, 189-191
  - VerifyNow Aspirin Assay, 189
- bleeding time, 183
- clinical settings for, 191t
- flow cytometry, 185
- functional abnormalities
  - acquired, 184, 188t, 188t
  - hereditary, 184, 186t-187t
- hemostatic potential assessments, 183
- individual variability and, 191, 192
- measurement, clinical outcomes and, 196
- measurement tools, 105
- thrombin generation assessments, 191, 192

Platelet glycoprotein. See *Glycoprotein (GP)*.

Platelet glycoprotein receptor antagonists. See *Glycoprotein IIb/IIIa receptor antagonists*.

Platelet inhibition. See *Antiplatelet agents*.

Platelet polymorphisms, 105

Platelet response variability, 195-211

- aspirin response variability, 95-97, 198, 199t
- clopidogrel response variability, 200-201, 202t-203t
- periprocedural management of therapy, 206, 206t
- platelet function measurement and clinical outcomes, 196
- posttreatment, 201
- stent thrombosis, 195-196, 197, 207t
- triple antithrombotic therapy, 204-206

Platelet roles, 16, 17t, 25-29, 26. See also *Clotting factor roles and fibrinolysis*.

- binding proteins, 28, 32
- cell-based model of coagulation, 27-28, 28
- cell interactions in, 28, 30-31
- platelet biology, 25-28, 26
  - activation, 25-27
  - adhesion, 26
  - aggregation, 27
  - chain of events in thrombosis, 26
  - measurement tools, 105
  - secretion, 27
  - support of coagulation, 27-28, 28

Plateletworks assay, 189

PLATO trial, 295

Plavix. See *Clopidogrel (Plavix)*.

Point-of-care monitoring instruments, 105, 183, 185, 191, 236, 249, 360, 362

Postoperative thromboembolism prevention, 36-37, 36t, 37t

Postphlebotic syndrome, 278-280

Potassium, 34

Prasugrel (Effient), 151-160, 188

- acquired platelet defects and, 188t
- actions of, 151-152
- chemical structure, 151
- clinical experience: acute coronary syndromes, 152-153, 249, 254t
  - TRITON study, 152-153, 154t-155t, 156, 158-159
- complications of (bleeding), 152-153, 154t-155t, 158-159, 249
- dosing, 151-152
- future directions and, 206
- pharmacodynamics, 151-152
- pharmacogenetics, 152
- pharmacokinetics, 151
- safety vs efficacy, balance of, 256t-257t

Pregnancy, 34

- anticoagulants in, 315t
  - bone loss in, 405
  - fibrinolytic therapy and, 78
  - heparins and, 34, 404-405
  - prosthetic heart valve issues, 335, 405
  - thrombophilia and, 214t, 219, 220t, 221
    - management of, 224
  - venous thromboembolism management in, 379-380
  - warfarin and, 398, 405
- Prekallikrein (PK), 15, 18

- PREMIER study, 195
- PREPARE POST-STENTING study, 201
- PREVENT trial, 379
- Prevention
- of MI, 85-86, 92-93
  - of stroke, 308-309, 313t-319t
  - of thrombosis. See *Thromboprophylaxis*.
  - of vascular events. See *Vascular event prevention*.
- Priming/amplification stage, 27, 28
- PRISM trial, 167, 170t-171t
- PRISM-PLUS trial, 167-168, 170t-171t
- Procoagulant/anticoagulant factors. See *Clotting factor roles and fibrinolysis*.
- Prodrug, 53, 145, 147
- PROFESS, 311t
- PROLONG trial, 379
- Propafenone, 56t
- Propagation stage, 27, 28
- Prophylaxis. See *Prevention*.
- Proplex-T, 396
- Propranolol, 56t, 395t
- Prostacyclin, 20
- Prosthetic heart valve thrombosis, 232, 233t, 328-329
- Prosthetic heart valves. See *Valvular heart disease*.
- Protamine, 35, 38t, 401
- Protein C, 16, 16t, 17, 374. See also *Activated protein C (APC)*.
- deficiency
    - thrombophilia and, 214, 215, 217-218, 219-221, 220t, 223
    - warfarin and, 55, 397
    - gene mutations, 214t, 217
- Protein S, 16t, 17, 374
- deficiency
    - thrombophilia and, 214, 215, 217-218, 219-221, 220t, 223
    - warfarin and, 55, 397
    - gene mutations, 214t, 217
- Prothrombin, 16t, 222
- G20210A mutation, 214t, 215, 218-219, 374
  - increased, 215
- Prothrombin complex concentrate (Proplex-T), 396
- Prothrombin time (PT)
- cautions for interpreting, 232
  - heparins and, 33, 231-232
  - INR, 223-224, 231-232, 391
  - warfarin and, 54, 55, 376
- Prothrombinase complex, 16, 17
- ProTime device, 360
- Proton pump inhibitors, 84, 147
- Prourokinase (saruplase), 71, 72t, 75
- P-selectin, 15, 196
- Pseudo von Willebrand's disease, 187t
- PT. See *Prothrombin time (PT)*.
- Pulmonary embolism (PE), 365-390. See also *Venous thromboembolic disease and pulmonary embolism*.
- anatomy and pathophysiology, 365-367
  - complications of, 382-383, 383t
  - CTPH, 383
  - diagnosis, 367, 372
- Pulmonary embolism (PE) (*continued*)
- diagnostic testing, 372, 372
  - incidence, 365
  - management of, 382-383, 383t
    - alteplase, 382-383, 383t
    - fondaparinux, 37t, 382, 383t
    - heparins, 37t, 382-383, 383t
    - thromboprophylaxis, 37t
  - scoring system, 369t, 370
  - signs and symptoms, 368-370, 369t
- Purple toes syndrome, 398
- PURSUIT scores, 250t
- PURSUIT trial, 169, 172
- Quadruple antithrombotic therapy, 205
- Race/ethnicity, in thrombophilia, 215
- RACE study, 347-348
- Rapid platelet function assay, 188-189, 190, 191t, 198
- RAPPORT, 166
- Rate control, 347-348
- Rattlesnake venom, 168
- Re-endothelialization, 328
- RE-LY trial, 349, 350
- Recombinant factor VIIa (NovoSeven), 57, 396, 401
- Recombinant hirudins, 47
- Recombinant tissue plasminogen activator (alteplase), 65-66
- Refludan. See *Lepirudin (Refludan)*.
- Refractory ischemia, 41, 42, 45, 74, 140, 167-168, 170t-171t, 178, 191t, 251
- Regurgitation, valvular, 267t, 346
- Reinfarction. See *Myocardial infarction (MI)*.
- Renal failure/impairment
- acquired platelet defects and, 188t
  - argatroban and, 53
  - fondaparinux and, 39, 400
  - heparins and, 34-35, 399-400
  - prasugrel and, 151
- Reocclusion, 46, 46, 66, 69, 73, 96, 275, 283, 406-407. See also *Occlusion*.
- ReoPro. See *Abciximab (ReoPro)*.
- Reperfusion, 77-79, 283-287
- resistance to, 283-287, 284
  - timing of, 77
- REPLACE 2 trial, 258
- Reptilase, 189
- Research studies. See *Clinical trials and research studies*.
- Resistance
- aspirin, 95-97, 105, 108
  - PAI-1, 71, 72t
  - thrombolytic, 283-287, 284
- Response variability. See *Variability in response*.
- Restenosis, 167
- RESTORE trial, 167, 175
- Retepase (rPA), 68t, 73, 74
- adjunctive therapy with, 76
  - in AMI, 278
- Revascularization, 263t

Rhythm management, 347-348. See also *Atrial fibrillation (AF)*.  
 Rifampin, 56t, 395t

Risk assessments and stratification. See also *Stroke, risk factors*.  
 ACSs, 241-243, 242t, 243t, 244-247, 248t, 250t-251t, 252  
 hemorrhagic risk, 334t  
 myocardial ischemia/infarction, 241-243, 248t, 250t-251t, 252, 289t  
 periprocedural risk, 206, 206t, 207t  
 stent thrombosis, 207t  
 thromboembolic risk, 333t

Rivaroxaban, 348, 349-351, 351, 361-362  
 half-life, 349

ROCKET-AF, 349-351, 351

Rolling, 15, 25

rPA (reteplase), 68t, 73, 74, 284, 285  
 adjunctive therapy with, 76  
 in PE, 383t

RPFA-ASA (Rapid Platelet Function Assay-ASA), 198

Salicylate, 101, 276

SALT, 311t

Saphenous vein graft occlusion, 87-91, 322  
 ticlopidine and, 117-121, 120t

Saruplase, 71, 72t, 75

Scoring systems (DVT and PE), 368, 369t, 370

scu-PA, 65

Selective factor Xa inhibitors, 36t, 37-47, 37t. See also *Fondaparinux; Rivaroxaban*.

Serotonin, 27

Signaling interactions, 30, 101, 196

SimpliRed, 370

SK (streptokinase), 68t, 69-70, 69

Skin/muscle necrosis  
 heparin and, 403  
 warfarin and, 55, 392t, 397

Smoke (tobacco), 105

SPAF studies, 232, 346, 354

SPEED trial, 285

Spinal hematoma, 35, 52, 400

Spinal subarachnoid hematoma, 400

ST-segment elevation myocardial infarction. See *STEMI*.

Stable angina. See *Angina, stable*.

Staphylokinase, 71, 72t, 76

Statins, 20  
 effect on hemostasis, 21

STEMI (ST-segment elevation myocardial infarction), 240. See also *Myocardial infarction (MI)*.  
 ASA vs warfarin therapy after, 296t  
 clopidogrel and, 144  
 electrocardiogram, 275  
 fibrolytic use, contraindications and cautions, 78t  
 plaques in, 240  
 prasugrel and, 153, 158-159

Stent thrombosis, 195-196, 197  
 platelet reactivity and, 200-201  
 risk stratification, 207t  
 triple therapy and, 205

Stents  
 bare-metal (BMS), 195-196, 197  
 coronary, 77  
 clopidogrel and, 135-140, 145, 146  
 ticlopidine and, 121, 125  
 drug-eluting (DES), 195-196, 197  
 periprocedural management of antiplatelet therapy, 206, 206t  
 posttreatment platelet response variability, 201  
 pre-assessment for, 206, 206t, 207t

Sticky platelet syndrome, 219

STIMS, 118t

Storage pool disease, 186t

Streptokinase (SK), 68t, 69-70, 69  
 allergic reactions to, 70, 279  
 in AMI, 275, 276, 285  
 aspirin with, 70  
 complications of, 407  
 in PE, 381, 383t

Stroke, 308-309. See also *Myocardial infarction (MI); Peripheral arterial vascular disease and stroke*.  
 AF and, 343, 344, 345, 345t, 346t, 351-354  
 aspirin and, 85-86, 91, 92-93, 94t-95t, 96t, 308  
 cardioembolic, 314t-315t, 343, 344  
 CHADS2 score, 204, 346, 347t, 361  
 clinical trials and research studies, 310t-311t  
 CAPRIE, 132-133, 134t, 135, 136, 310t  
 CAST, 310t  
 CATS, 118t, 125, 310t  
 Chinese Stroke Trial, 61  
 ESPS-2, 310t  
 International Stroke Trial, 91  
 IST, 311t  
 MAST-1, 311t  
 PROFESS, 311t  
 SALT, 311t  
 TASS, 118t, 125-126, 311t  
 TISS, 118t, 311t  
 UK-TIA, 311t

cryptogenic, 315t  
 fondaparinux and, 43-46, 46  
 heparins and, 36  
 ischemic, 308-309, 308  
 treatment/prevention of, 310t-317t  
 noncardioembolic, 314t  
 PAD, 308, 309-317  
 prevention, 308-309, 313t-319t  
 antiplatelet agents, 351-354  
 aspirin, 85-86, 91, 92-93, 94t-95t, 96t, 351-352, 360-361  
 clopidogrel, 354-355  
 rivaroxaban, 349-351, 351  
 ticlopidine, 354-355  
 warfarin, 348t, 350-354, 352t, 353, 360-361, 361  
 risk factors and their management, 309, 314t-315t, 351-354, 353t  
 AF and, 343, 344, 345, 345t, 347t, 351-354, 356t  
 treatments for, 308-309, 310t-315t  
 aspirin, 122t-124t, 125-126, 127t, 308

- Stroke, treatments for (*continued*)  
 platelet antagonist therapy, 310t-311t  
 ticlopidine, 118t, 120t, 122t-124t, 125-126, 127t
- Sucralfate, 56t, 394, 395t
- Sulfipyrazone, 56t, 395t
- Surgery. See also *Hip surgery*; *Orthopedic surgery*.  
 anticoagulant use in, 400t  
 peripheral vascular reconstructive, 322-324
- Swedish Ticlopidine Multicenter Study, 125
- Synthetic factor Xa inhibitor. See *Fondaparinux (Arixtra)*.
- Systemic lytic state, 65, 69, 75
- TACTICS-TIMI trial, 168
- TAFI (thrombin activatable fibrinolysis inhibitor), 18
- Tamoxifen, 395t
- TARGET trial, 136-137, 175, 176t
- TASS, 118t, 125-126
- TEE (transesophageal echocardiography), 346, 346t
- Tenase complex, 16, 17
- Tenecteplase (TNK-tPA), 68t, 73-75, 74  
 adjunctive therapy with, 76
- TF (tissue factor), 15, 17, 20, 28
- TFPI (tissue factor plasminogen inhibitor), 15, 16t, 17  
 gene mutations, 214t  
 heparins and, 34
- Therapeutic window, 357, 358
- Therapy. See *Antithrombotic therapy*.
- Thienopyridine, 97, 294  
 derivative agents. See *Clopidogrel*; *Prasugrel*; *Ticlopidine*.  
 vs aspirin, 127t
- Thrombectomy, 381
- Thrombin, 16, 17-18, 32  
 fibrin-bound, 33, 38t, 283, 284, 406  
 heparins and, 33, 34, 38t, 283  
 generation/regulation of, 16-17, 18t, 27, 284  
 variability in, 191, 192  
 hirudins and, 47-48  
 inactivation/inhibition of. See *Antithrombotic agents*.  
 resistance due to activation of, 283-287, 284
- Thrombin activatable fibrinolysis inhibitor (TAFI), 18
- Thrombocytopenia  
 antithrombotic agents and, 38t, 392t  
 GP IIb/IIIa receptor antagonists and, 165, 166, 177  
 heparins and, 35, 38t, 401-403  
 ticlopidine and, 116
- Thromboelastography, 189-191
- Thromboembolic risk. See *Risk assessments and stratification*.
- Thrombolysis. See *Fibrinolysis*; *Fibrinolytic agents*.
- Thrombolysis in Myocardial Infarction. See *TIMI*.
- Thrombolysis reperfusion, 77
- Thrombolytic resistance, 283-287, 284
- Thrombomodulin (TM), 16-17, 18t, 222  
 gene mutations, 214t
- Thrombophilia, 213-230  
 acquired, 219-224  
 antiphospholipid syndrome, 214t, 220t, 221-222
- Thrombophilia (*continued*)  
 definition/description, 213  
 diagnosis, 222-223, 223t  
 etiology, 215-218  
 FURY mnemonic, 222, 223t  
 FVL, 214, 214t, 215-216  
 heparin cofactor II, 218  
 hyperhomocysteinemia, 214t, 215, 216-217, 217t  
 incidence/prevalence of, 214-215, 215  
 inherited, 213-218, 214t  
 thrombosis risks in, 214-215  
 location of thrombi, 218-219  
 management of, 223-224  
 platelet abnormalities, 219  
 proteins C, S, and AT, 214, 214t, 215, 217-218, 219-221  
 prothrombin G20210A, 214t, 215, 216  
 thrombosis risks in, 214-215, 219  
 warfarin and, 223-224  
 when to investigate for, 213
- Thromboprophylaxis  
 antithrombotic agents for, 36, 36t, 39  
 fondaparinux and, 36t, 39  
 heparins and, 36, 36t  
 rivaroxaban and, 349-351, 351  
 for venous thromboembolism, 373-374
- Thrombosis. See also *Antithrombotic agents*.  
 atherosclerosis and, 307, 308  
 chain of events in, 26  
 clotting factors and. See *Clotting factor roles*.  
 initiation of, 15-16, 17t  
 pharmacologic control of, 188  
 physiology, 15-23  
 steps in, 25, 26  
 platelet events in, 25-28, 26  
 prevention of. See *Thromboprophylaxis*.  
 risk scales/stratification, 333t, 334t  
 stent thrombosis, 195-196, 197  
 tendency toward. See *Thrombophilia*.  
 venous, 365-366
- Thrombotic disorders. See also *specific disorders*.  
 DVT and, 365-390  
 thrombophilia, 213-230
- Thrombotic thrombocytopenic purpura (TTP)  
 clopidogrel and, 132  
 ticlopidine and, 116, 126
- Thromboxane, 188
- Thromboxane A<sub>2</sub> synthesis, 20, 95, 97
- Thromboxane B<sub>2</sub> synthesis, 96, 102t
- Thrombus initiation, 15-16, 17t. See also *Clotting factor roles and fibrinolysis*.
- TIAs (transient ischemic attacks)  
 aspirin and, 91, 310t  
 clinical trials, 310t-311t  
 prevention, 308-309, 314t-319t  
 ticlopidine and, 118t, 120t, 127t, 310t
- Ticagrelor, 91, 188, 206  
 acquired platelet defects and, 188t

- Ticloid. See *Ticlopidine (Ticloid)*.
- Ticlopidine (Ticloid), 115-130, 188. See also *Antiplatelet agents*.
- acquired platelet defects and, 188t
  - in ACSs, 254t
  - in AF, 354-355
  - allergic reactions, 116
  - aspirin vs, 117, 121, 122t-124t, 125, 127t
  - clinical experience, 116-126, 118t-119t, 120t, 122t-124t
    - angina pectoris, stable, 117
    - angina, unstable, 117
    - CABG, 117-121, 118t
    - coronary arterial stenting, 121, 125
    - coronary artery disease, 117, 118t
    - diabetic retinopathy, 119t
    - myocardial infarction (MI), 117
    - peripheral vascular disease, 121-125
    - stroke, 125-126, 127t
  - clinical trials and research studies, 117-126, 118t-119t, 120t, 122t-124t
    - CATS, 118t, 125, 310t
    - EMATAP, 118t
    - EPISTENT, 116, 121
    - FANTASTIC, 121
    - MATTIS, 121
    - STIMS, 118t
    - Swedish Ticlopidine Multicenter Study, 125
    - TASS, 118t, 125-126, 311t
    - TISS, 118t
    - TMD, 119t
  - clopidogrel vs, 116, 126, 132
  - drug-drug interactions, 116
  - effects of
    - on fibrinogen binding, 115
    - in vitro* effects, 115
    - in vivo* effect on platelet function, 115
    - nonplatelet effects, 115
    - monitoring recommendations, 116, 126
    - pharmacokinetics, 115-116
    - as pro-drug, 115, 126
    - side effects, 116, 117, 126
      - bone marrow suppression, 116, 126
      - thrombocytopenia, 392t
      - TTP, 116, 126
    - in TIAs and stroke, 308, 310t-311t, 354-355
    - vs aspirin, 117, 121, 122t-124t, 125, 127t
- TIMI (Thrombolysis in Myocardial Infarction), 41, 43, 66
- risk scores, 242, 248t, 250t, 252
  - TIMI 3 flow, 278
  - TIMI-3 plateaus, 291
  - TRITON-TIMI38, 249
- TIMI trials, 249, 251, 284-285, 285
- Timing of therapy, 77-79
- Tinzaparin (Innohep), 36, 36t, 37t, 399
- in DVT, 374, 375t
- Tirofiban (Aggrastat), 165-168, 188. See also *Glycoprotein IIb/IIIa receptor antagonists*.
- in ACSs, 254t
- Tirofiban (Aggrastat) (*continued*)
- clinical trials and experience, 167-170, 170t-171t, 175, 176t
  - distinguishing characteristics, 172-174, 173t, 174, 175
  - pharmacodynamics, 167
  - TARGET trial, 136-137, 175, 176t
  - TISS, 118t
- Tissue factor (TF), 15, 17, 20
- vs contact-activated coagulation, 28
- Tissue factor-bearing cells, 27, 28
- Tissue factor plasminogen inhibitor (TFPI), 15, 17
- heparins and, 34
- Tissue plasminogen activator. See *tPA*.
- TM. See *Thrombomodulin (TM)*.
- TMD study, 119t
- TNK-tPA (tenecteplase), 68t, 73-75, 74
- adjunctive therapy with, 76
  - in AMI, 278
  - in PE, 383t
- Tobacco-mediated platelet activation, 105
- tPA (tissue plasminogen activator), 18, 19, 65-66, 67, 381. See also *Plasminogen activators*.
- ACCP, AHA, and ESO guidelines for, 312t-313t
  - action mechanism, 65, 67
  - in AMI, 279
  - antiplatelet therapy prior to, 66
  - clinical features of, 68t
  - exclusion criteria for, 312t
  - mutant forms of, 73-76
    - rPA (reteplase), 68t, 73, 74
    - TNK-tPA (tenecteplase), 68t, 73-75, 74, 278
  - recombinant (alteplase), 65-66, 382-383, 383t
  - structure of, 65, 67
  - UFH simultaneously with, 66
- Transesophageal electrocardiography (TEE), 346, 346t
- Transient ischemic attacks. See *TIAs*.
- Transthoracic electrocardiography (TTE), 346, 346t
- Treatment. See *Antithrombotic therapy*.
- Trials, clinical. See *Clinical trials and research studies*.
- Triple antithrombotic therapy, 204-206
- TRITON study, 145, 152-153, 154t-155t, 156, 158-159, 294
- TRITON-TIMI38, 249
- Troponin, 249, 258
- TTE (transthoracic electrocardiography), 346, 346t
- TTP (thrombotic thrombocytopenic purpura)
- clopidogrel and, 132
  - ticlopidine and, 116, 126
- Turbidimetric platelet aggregometry, 184
- TXA<sub>2</sub> synthesis, 20, 95, 97
- TXB<sub>2</sub> synthesis, 96, 102t
- Ubidecarenone (Coenzyme Q10), 398
- UFH (unfractionated heparin). See *Heparins*.
- UK-TIA trial, 311t
- Ulcer, peptic, 78, 84
- Ultegra, 198
- Unfractionated heparin (UFH). See *Heparins*.

- Unstable angina (UA). See *Angina, unstable*.
- Urokinase, 381, 383t  
 single-chain urokinase plasminogen activator (scu-PA), 65  
 urokinase plasminogen activator (prourokinase; saruplase), 71, 72t, 75
- Valvular heart disease, native and prosthetic, 327-341  
 anticoagulant therapy, 332-334, 336t-339t  
 aortic valve, blood flow across, 328, 330  
 bridging therapy, 335  
 clinical experience, 332  
 early postoperative therapy, 334-335  
 management guidelines, 332-334, 336t-339t  
 mitral annular calcification (MAC), 337t  
 mitral valve, blood flow across, 328, 331  
 native valvular heart disease, 332, 336t-338t  
 pathobiology, 327-328  
 prevalence, 327  
 prosthetic heart valves, 328-329, 332, 339t  
 antithrombotic therapy, summary, 339t  
 bileaflet, 338t, 339t  
 bioprosthetic, 329, 333t  
 Bjork-Shiley (tilting-disk), 333t, 339t  
 caged-ball/disk, 333t, 338t, 339t  
 mechanical, 329, 338t  
 pregnancy and, 405  
 St. Jude mechanical, 333t  
 thrombosis and, 232, 233t, 328-329, 332  
 tissue (bioprosthetic), 329, 333t  
 re-endothelialization and, 328  
 risk assessments and stratification, 332, 333t, 334t  
 scope of problem, 327  
 valvular thrombi, natural history of, 328
- Valvular regurgitation, 267t, 346
- Variability in response  
 to aspirin, 95-97, 198, 199t  
 to clopidogrel, 200-201, 202t-203t  
 of platelets, 195-211. See also *Platelet response variability*.
- Vascular disease. See *Peripheral arterial vascular disease and stroke*.
- Vascular event prevention  
 aspirin and, 85-86, 85, 91  
 primary prevention, 85-86, 88-90, 92-93, 94t-95t, 96t  
 secondary prevention, 86, 91, 98-100
- Vascular factors in thrombus formation, 18-20, 30-31
- Vascular grafts, 36-37, 87-91
- Vasospasm, 242t, 307, 322t
- VASP index, 201
- Vena cava filters, 384
- Venous and arterial diseases. See *Clinical syndromes*.
- Venous gangrene, 399, 403
- Venous system, 366
- Venous thromboembolic disease and pulmonary embolism, 365-390  
 anatomy and pathophysiology, 365-366, 366  
 clinical trials and research studies  
 ATTRACT, 382  
 PREVENT, 379  
 PROLONG, 379
- Venous thromboembolic disease and pulmonary embolism (*continued*)  
 complications of, 380-384  
 CTPH, 383  
 postphlebotic syndrome, 380-382  
 vena cava filters, 384  
 diagnosis, 367, 371  
 incidence, 365  
 laboratory/diagnostic testing, 370-372, 371, 372  
 management of, 372-380  
 duration of treatment, 377-379  
 DVT, 374-376  
 fondaparinux, 39-41, 42, 373-374, 375t, 382, 383t  
 heparins, 374, 375t, 382, 383t  
 outpatient therapy, 376-377  
 PE, 382-383, 383t  
 pregnancy and, 379-380  
 thromboprophylaxis, 373-374  
 warfarin, 375-376  
 scoring systems, 368, 369t, 370  
 signs and symptoms, 368-370, 369t  
 stages of, 366-367  
 VTE. See *Venous thromboembolism*.
- Venous thromboembolism (VTE), 218  
 dabigatran etexilate for, 53  
 pregnancy and, 379-380  
 prophylaxis, 373-374  
 UFH regimens for, 235t
- VerifyNow Aspirin Assay, 189, 201  
 VerifyNow P2Y<sub>12</sub> Assay, 189
- Virchow's triad, 328, 365
- Vitamin K, 394  
 antagonist (VKA) therapy, 204-206, 320t-321t, 336t-338t  
 deficiency, 220t, 221  
 warfarin and, 55, 355  
 for warfarin-induced bleeding, 397
- VKORC1 (vitamin K epoxide reductase complex 1), 55, 376, 393
- von Willebrand's disease, 183, 186t-187t
- von Willebrand's factor (vWF), 17, 20, 25, 32  
 heparin binding to, 33  
 ticlopidine and, 115
- VTE. See *Venous thromboembolism*.
- VWF. See *von Willebrand's factor*.
- Warfarin (Coumadin), 54-57. See also *Antithrombotic agents*.  
 in ACSs, 258  
 adverse reactions, 55, 397-398  
 in AF, 348, 351-352, 352t, 353, 353t, 355-357, 356-358, 356t, 361, 396  
 age factors and, 356, 375  
 AMI and, 295-298, 296t, 297t  
 binding by plasma proteins, 54  
 combination therapy (with aspirin), 324  
 complications of, 391-398, 392t  
 adverse reactions other than bleeding, 397-398  
 age/gender factors, 393-394  
 bleeding, 224, 352-354, 353, 353t, 391-398, 392t  
 changes and duration of treatment, 395-396

Warfarin (Coumadin), complications of (*continued*)  
  diet and, 394  
  drug interactions, 55, 56t, 394, 395t  
  duration of treatment  
  genetic factors, 393  
  hemorrhage/bleeding, 358, 391-394, 393t  
    management of, 396-397  
  risk factors, 393-395, 393t  
  tissue necrosis, 55  
coumarins, 54  
  dosage, 355, 357, 375-376  
  dose variability, 375-376  
  in DVT, 374-376, 375t  
  half-life, 54  
  ISI and, 54  
  monitoring, 54, 231-232, 355-357  
  number needed to treat, 351-352, 352t  
  polymorphisms and, 54-55  
  pregnancy and, 398, 405  
  response variability, 334-335  
  risk stratification and reduction, 351-352, 352t  
  risks vs benefits, 352-354, 353, 353t, 355-357, 358  
    lowest effective intensity, 357  
  safety issues, 348  
  in thrombophilia, 223-224  
  in TIAs and stroke, 309, 314t-315t  
  transitioning to other agents, 359  
  utilization of, 360-361, 361  
  in valvular heart disease/thrombosis, 334  
  vitamin K and, 55, 397  
  vs dabigatran etexilate, 349, 350  
  vs rivaroxaban, 349-351, 351  
  in VTE prophylaxis, 374  
WARIS trials, 295, 296t, 297t  
WOEST trial, 206

Ximelagatran, 53